These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37783974)

  • 1. Sharing Adverse Drug Event Reports Between Hospitals and Community Pharmacists to Inform Re-dispensing: An Analysis of Reports and Process Outcomes.
    Cragg A; Small SS; Lau E; Rowe A; Lau A; Butcher K; Hohl CM
    Drug Saf; 2023 Nov; 46(11):1161-1172. PubMed ID: 37783974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using ActionADE to create information continuity to reduce re-exposures to harmful medications: study protocol for a randomized controlled trial.
    Hau JP; Brasher PMA; Cragg A; Small S; Wickham M; Hohl CM
    Trials; 2021 Feb; 22(1):119. PubMed ID: 33546752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing and Comparing Adverse Drug Events Documented in 2 Spontaneous Reporting Systems in the Lower Mainland of British Columbia, Canada: Retrospective Observational Study.
    Lau EY; Cragg A; Small SS; Butcher K; Hohl CM
    JMIR Hum Factors; 2024 Jan; 11():e52495. PubMed ID: 38236629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An external facilitation intervention to increase uptake of an adverse drug event reporting intervention.
    Lau EY; Small SS; Butcher K; Cragg A; Loh GW; Shalansky S; Hohl CM
    Front Health Serv; 2023; 3():1106586. PubMed ID: 37332530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Drug Events Detected by Clinical Pharmacists in an Emergency Department: A Prospective Monocentric Observational Study.
    Laureau M; Vuillot O; Gourhant V; Perier D; Pinzani V; Lohan L; Faucanie M; Macioce V; Marin G; Giraud I; Jalabert A; Villiet M; Castet-Nicolas A; Sebbane M; Breuker C
    J Patient Saf; 2021 Dec; 17(8):e1040-e1049. PubMed ID: 32175969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of attitudes on pharmacists' intention to report serious adverse drug events to the Food and Drug Administration.
    Gavaza P; Brown CM; Lawson KA; Rascati KL; Wilson JP; Steinhardt M
    Br J Clin Pharmacol; 2011 Jul; 72(1):143-52. PubMed ID: 21332572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examination of pharmacists' intention to report serious adverse drug events (ADEs) to the FDA using the theory of planned behavior.
    Gavaza P; Brown CM; Lawson KA; Rascati KL; Wilson JP; Steinhardt M
    Res Social Adm Pharm; 2011 Dec; 7(4):369-82. PubMed ID: 21272531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergency hospitalizations for adverse drug events in China: Clinical pharmacists' approach to assessment and categorization.
    Zhang Y; Jin L; Zhang X; Bai R; Chen D; Ma Y; Zhai X
    Pharmacoepidemiol Drug Saf; 2021 May; 30(5):636-643. PubMed ID: 33630347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of social influences on pharmacists' intention to report adverse drug events.
    Gavaza P; Brown CM; Lawson KA; Rascati KL; Steinhardt M; Wilson JP
    J Am Pharm Assoc (2003); 2012; 52(5):622-9. PubMed ID: 23023842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automated surveillance for adverse drug events at a community hospital and an academic medical center.
    Kilbridge PM; Campbell UC; Cozart HB; Mojarrad MG
    J Am Med Inform Assoc; 2006; 13(4):372-7. PubMed ID: 16622159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and prevalence of adverse drug events caused by potentially inappropriate medication in homebound elderly patients: a retrospective study using a nationwide survey in Japan.
    Onda M; Imai H; Takada Y; Fujii S; Shono T; Nanaumi Y
    BMJ Open; 2015 Aug; 5(8):e007581. PubMed ID: 26260347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database.
    Sonawane KB; Cheng N; Hansen RA
    J Manag Care Spec Pharm; 2018 Jul; 24(7):682-690. PubMed ID: 29952714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of a pharmacist-led adverse drug event management model for pharmacovigilance in an academic medical center hospital in China.
    He W; Yao D; Hu Y; Dai H
    Ther Clin Risk Manag; 2018; 14():2139-2147. PubMed ID: 30464487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing medication errors for adults in hospital settings.
    Ciapponi A; Fernandez Nievas SE; Seijo M; Rodríguez MB; Vietto V; García-Perdomo HA; Virgilio S; Fajreldines AV; Tost J; Rose CJ; Garcia-Elorrio E
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD009985. PubMed ID: 34822165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Texas pharmacists' opinions on reporting serious adverse drug events to the Food and Drug Administration: a qualitative study.
    Gavaza P; Brown CM; Khoza S
    Pharm World Sci; 2010 Oct; 32(5):651-7. PubMed ID: 20652830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for hospital admissions associated with adverse drug events.
    Kongkaew C; Hann M; Mandal J; Williams SD; Metcalfe D; Noyce PR; Ashcroft DM
    Pharmacotherapy; 2013 Aug; 33(8):827-37. PubMed ID: 23686895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential cost savings by prevention of adverse drug events with a novel medication review program.
    Fernández EV; Warriner CL; David T; Gordon E; Twigg G; Carroll NV
    J Am Pharm Assoc (2003); 2020; 60(3):462-469.e4. PubMed ID: 31948934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perceived barriers to reporting adverse drug events in hospitals: a qualitative study using theoretical domains framework approach.
    Mirbaha F; Shalviri G; Yazdizadeh B; Gholami K; Majdzadeh R
    Implement Sci; 2015 Aug; 10():110. PubMed ID: 26250159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of a computerized drug-monitoring program to detect and prevent adverse drug events and medication non-adherence in outpatient ambulatory care: study protocol of a randomized controlled trial.
    Forster AJ; Erlanger TE; Jennings A; Auger C; Buckeridge D; van Walraven C; Tamblyn R
    Trials; 2015 Jan; 16():2. PubMed ID: 25572800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study.
    de Vries ST; Haaijer-Ruskamp FM; de Zeeuw D; Denig P
    Health Qual Life Outcomes; 2014 Aug; 12():103. PubMed ID: 25115618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.